Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2022
Reporting Period: Fiscal First Quarter ended March 31, 2022
This filing serves as a notification that the Company announced its financial results for the first quarter of 2022 via a press release dated May 10, 2022. The press release is incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing explicitly states that the detailed results are contained in the attached press release (Exhibit 99.1), which is furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms the announcement of Q1 2022 results.
Guidance, Outlook, and Risks
Management Commentary: The text confirms the issuance of a press release regarding Q1 2022 results but does not include the content of that commentary.
Guidance and Outlook: Not provided in this text.
Risks and Contingencies: Not provided in this text.
Unusual Items: Not provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 10, 2022) for actual revenue, net income, and cash flow figures.
- Verify the specific details of the "Results of Operations and Financial Condition" referenced in Item 2.02.
- Check for any forward-looking statements or updated guidance within the attached press release.
- Confirm the status of the Class A Common Stock (Trading Symbol: ORGO) on the Nasdaq Capital Market.